Europe
FoRx Therapeutics AG, the biotechnology company developing a new generation of cancer drugs focusing on novel DNA Replication Stress pathways, announced the closing of a EUR 10 million seed financing led by M Ventures, Novartis Venture Fund and Omega Funds.
Nuritas, a biotech company that focuses on leveraging artificial intelligence (AI) to discover therapeutic peptides, is joining the fight by tasking their powerful AI platform to find peptides that can be used as therapeutics for COVID-19.
Despite the domination of the news cycle by the COVID-19 pandemic, quite a number of biopharma companies reported on non-COVID-19 clinical trials last week, although there remains plenty of ongoing trial news related to the pandemic. Here’s a look.
David Loew, head of Sanofi Pasteur, said U.S. approval of the vaccine is an important milestone in the fight against meningococcal meningitis, a serious global health challenge that can be fatal within 24 hours.
AstraZeneca and Merck & Co. released more positive data from the Phase III PROfound trial of Lynparza (olaparib) in metastatic castration-resistant prostate cancer.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 24, 2020.
Biopharma and life sciences companies bolster their leadership teams and boards with this week’s Movers & Shakers.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
The COVID-19 pandemic is having a devastating effect on global business and biopharma companies are not excluded.
The company said the treatment significantly reduced disease activity as measured by magnetic resonance imaging.
PRESS RELEASES